Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck Serono, Idera Partner On Cancer
December 24, 2007
| A version of this story appeared in
Volume 85, Issue 52
Merck Serono and Idera Pharmaceuticals will develop Idera's toll-like receptor 9 (TLR9) agonists for the treatment of cancer. Under the agreement, Idera will exclusively license the oncology application of its lead TLR9 agonists, IMO-2055 and IMO-2125-excluding their use with cancer vaccines-to Merck Serono. The companies will also collaborate on identifying new TLR9 agonists using Idera's chemistry-based discovery approach. Merck will have the exclusive right to develop them in nonvaccine applications. Merck will pay Idera an up-front license fee of $40 million and possibly $381 million more in milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter